Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease

被引:10
作者
Chien, Yin-Hsiu [1 ,2 ]
Olivova, Petra [3 ]
Zhang, Xiaokui Kate [3 ]
Chiang, Shu-Chuan [1 ,2 ]
Lee, Ni-Chung [1 ,2 ]
Keutzer, Joan [3 ]
Hwu, Wuh-Liang [1 ,2 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Med Genet & Pediat, Taipei 10016, Taiwan
[2] Natl Taiwan Univ, Sch Med, Taipei 10764, Taiwan
[3] Genzyme Corp, Framingham, MA 01701 USA
关键词
Urinary globotriaosylceramide; GL3; Fabry disease; Newborn screening; alpha-Galactosidase A; ENZYME REPLACEMENT THERAPY; TANDEM MASS-SPECTROMETRY; AGALSIDASE-BETA THERAPY; ALPHA-GALACTOSIDASE; DIAGNOSIS; SEDIMENT; EFFICACY; SAMPLES; SAFETY; CTH;
D O I
10.1016/j.ymgme.2010.08.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fabry disease is caused by a deficiency of alpha-galactosidase A (alpha-Gal A), which results in the accumulation of globotriaosylceramide (GL3) and related glycosphingolipids in different organs. Urinary GL3 levels increase in symptomatic Fabry disease patients, but it is not clear whether urinary GL3 excretion also increases in young or pre-symptomatic patients. Subjects and methods: Eighty-nine newborns with leukocyte alpha-Gal A activities of less than 30% of the normal mean were discovered by newborn screening. Urine samples were collected on filter paper, and GL3 levels were measured using liquid chromatography-tandem mass spectrometry. Results: Five newborns with classic Fabry disease mutations all had elevated urinary GL3 levels (mean = 5.2 mg/mmol creatinine (creat.), range = 0.80-14.39, normal <0.6). Among the 84 newborns with later-onset mutations, 45 (54%) had a mild elevation of urinary GL3 levels (mean = 1.1 mg/mmol creat., range = 0.60-3.07, normal <0.6). The urinary GL3 levels decreased in all newborns over the course of a three-year follow-up period. However, four children with classic mutations and seven with IVS4+919G>A mutations still had elevated GL3 levels at the end of the study. Conclusion: Elevated urinary GL3 levels can be present at birth in Fabry disease patients, suggesting an early involvement of the kidneys in this disease. The increased urinary GL3 excretion in those with later-onset mutations supports a pathogenic role for these mutations. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:57 / 60
页数:4
相关论文
共 26 条
[1]   Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease [J].
Auray-Blais, C. ;
Cyr, D. ;
Mills, K. ;
Giguere, R. ;
Drouin, R. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 (01) :106-106
[2]   Mass urinary screening for Fabry disease: Is it feasible? [J].
Auray-Blais, Christiane ;
Cyr, Denis ;
Clarke, Joe T. R. ;
Drouin, Rigen .
MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) :S15-S15
[3]   Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study [J].
Baehner, F ;
Kampmann, C ;
Whybra, C ;
Miebach, E ;
Wiethoff, CM ;
Beck, M .
JOURNAL OF INHERITED METABOLIC DISEASE, 2003, 26 (07) :617-627
[4]   Agalsidase-beta therapy for advanced Fabry disease - A randomized trial [J].
Banikazemi, Maryam ;
Bultas, Jan ;
Waldek, Stephen ;
Wilcox, William R. ;
Whitley, Chester B. ;
McDonald, Marie ;
Finkel, Richard ;
Packman, Seymour ;
Bichet, Daniel G. ;
Warnock, David G. ;
Desnick, Robert J. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) :77-86
[5]   Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months [J].
Barr, Caroline ;
Clarke, Joe T. R. ;
Ntwari, Aime ;
Drouin, Regen ;
Auray-Blais, Christiane .
MOLECULAR GENETICS AND METABOLISM, 2009, 97 (04) :278-283
[6]  
CHUANG W, ANAL SPHINGOLI UNPUB
[7]   DIAGNOSIS OF GLYCOSPHINGLOPIDOSES BY URINARY-SEDIMENT ANALYSIS [J].
DESNICK, RJ ;
DAWSON, G ;
DESNICK, SJ ;
SWEELEY, CC ;
KRIVIT, W .
NEW ENGLAND JOURNAL OF MEDICINE, 1971, 284 (14) :739-&
[8]   Fabry disease in childhood [J].
Desnick, RJ ;
Brady, RO .
JOURNAL OF PEDIATRICS, 2004, 144 (05) :S20-S26
[9]   Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy [J].
Desnick, RJ ;
Brady, R ;
Barranger, J ;
Collins, AJ ;
Germain, DP ;
Goldman, M ;
Grabowski, G ;
Packman, S ;
Wilcox, WR .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (04) :338-346
[10]  
Desnick RobertJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, V8th, P3733